|
|
| (38 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| − | {{pnc}} | + | {{gohome}} |
| | + | {{ft|P}} |
| | + | '''CHERRYPICKING STUDIES IS NOT SCIENCE |
| | + | {{qt|Reviews on covid drug development}} |
| | | | |
| − | current items will be put into the subsections.
| |
| | | | |
| − | *[[reviews on covid drug development]] | + | *'''[[scouting ideas]]''' |
| − | *[[scouting ideas]]
| + | |
| | | | |
| − | *[[Patients on biologicals]] | + | *'''[[PHA Biologicals]]''' |
| − | *[[HMGB1, RAGE]]
| + | |
| − | *[[pre-Interleukin 6]]
| + | |
| − | *[[post-Interleukin 6]]
| + | |
| − | *[[pre-TNFalpha]]
| + | |
| − | *[[post-TNFalpha]]
| + | |
| − | *[[pre-Interleukin 17]]
| + | |
| − | *[[post-Interleukin 17]]
| + | |
| − | *[[pre-Interleukin 1]]
| + | |
| − | *[[post-Interleukin 1]]
| + | |
| − | *[[Inflammasome]] ''colchicine''
| + | |
| − | *[[Methotrexate]]
| + | |
| − | *[[other anti-inflammatory]]
| + | |
| − | *[[NK-kappaB]]
| + | |
| − | *[[STAT 3]]
| + | |
| − | *[[JAK Janus Kinase]]
| + | |
| − | *[[Corticosteroids]]
| + | |
| − | *[[Cytokine absorbers]]
| + | |
| − | *[[Target Complement system]]
| + | |
| − | *[[Target Extracellular traps]]
| + | |
| − | *[[Anticoagulant in covid19]]
| + | |
| − | *[[Antioxidants]]
| + | |
| − | *[[Stem cells]]
| + | |
| − | *[[MDSC cells]]
| + | |
| − | *[[Interferons]]
| + | |
| | | | |
| | + | *'''[[PHA conventional pharmacology]]''' |
| | | | |
| − | *[[other single compounds]] | + | *'''[[PHA retargeted compounds]]''' |
| − | *[[Retargeted single compounds]]
| + | |
| − | *[[Hydroxychloroquine]]
| + | |
| − | *
| + | |
| − | *[[Target ACE2, Spike protein]]
| + | |
| − | *[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
| + | |
| − | *[[other antiviral compounds]]
| + | |
| − | *[[AV Remdesivir]]
| + | |
| − | *[[AV Lopinavir]]
| + | |
| − | *[[AV Ivermectin]]
| + | |
| − | *[[AV Arabidol]]
| + | |
| − | *[[AV Favipiravir]]
| + | |
| | | | |
| | + | *'''[[PHA antivirals by mechanism]]''' |
| | | | |
| | + | *'''[[PHA pharmacophore by screened target]]''' |
| | | | |
| − | *[[Vitamin D]] | + | *'''[[PHA ImmunoNutrients]] |
| − | *[[Anorganic nutrients Magnesium]]
| + | |
| − | *[[Anorganic nutrients Selenium]]
| + | |
| − | *[[Anorganic nutrients Zinc]]
| + | |
| − | *[[Nutrition, general]]
| + | |
| − | *[[Exercise, Vibration]]
| + | |
| | | | |
| | + | *'''[[PHA compl altern natural]]''' |
| | | | |
| − | *[[Traditional Chinese Medicine]] | + | *'''[[PHA within indications compounds]]''' |
| − | *[[Natural compounds]]
| + | |
| | | | |
| − | *[[Statins]] | + | *'''[[PHA Serum products]]''' |
| − | *[[Antidiabetic compounds, any]]
| + | |
| − | *[[RSP - On RAS drugs]]
| + | |
| | | | |
| − | *[[Reconvalescent blood products, Passive vaccine]] | + | *'''[[PHA Vaccination]]''' |
| − | *[[Plasmapheresis]]
| + | |
| | + | PHA related options: |
| | | | |
| − | *[[Immunodeviation]] e.g. by adjuvants or other vaccinations
| |
| | *[[Radiation therapy]] | | *[[Radiation therapy]] |
| | *[[Phototherapy]] | | *[[Phototherapy]] |
| − | *[[Active vaccine]] | + | *[[Electric fields]] |
| − | | + | *[[Treatment other concepts]] |
| − | ===008===
| + | |
| − | {{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32401611|t=2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32519258|t=2020. BCG Vaccination Policy and Protection Against COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32395606|t=2020. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32413736|t=2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32389723|t=2020. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32454071|t=2020. Is teicoplanin a complementary treatment option for COVID-19? The question remains.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32450201|t=2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32522674|t=2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32534189|t=2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534188|t=2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534187|t=2020. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32470577|t=2020. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534094|t=2020. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R)).|pdf=|usr=008}}
| + | |
| − | {{ttp|p=32398962|t=2020. A potential treatment of COVID-19 with TGF-beta blockade.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32435920|t=2020. Lithium's antiviral effects: a potential drug for CoViD-19 disease?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32382873|t=2020. Covid-19 and drug therapy, what we learned.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32460369|t=2020. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32412158|t=2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531935|t=2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32470602|t=2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32425638|t=2020. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32522597|t=2020. Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32502659|t=2020. Potential role of statins in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32521619|t=2020. Redox-Modulating Agents in the Treatment of Viral Infections.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32461554|t=2020. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32327922|t=2020. The 4 D's of Pellagra and Progress.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32447429|t=2020. Trials and tribulations: so many potential treatments, so few answers.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32483523|t=2020. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32426222|t=2020. The Ethics of COVID-19 Clinical Trials: New Considerations in a Controversial Area.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32488835|t=2020. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32458206|t=2020. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32411575|t=2020. Malnutrition Care during the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists Evidence Analysis Center.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32479759|t=2020. Successful use of methylprednisolone for treating severe COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32470486|t=2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32527713|t=2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32397940|t=2020. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32396773|t=2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32396769|t=2020. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32394467|t=2020. A global treatments for coronaviruses including COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32526460|t=2020. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32517353|t=2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32489508|t=2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425662|t=2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32384202|t=2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32388906|t=2020. Do novel drugs for diabetes help in COVID-19? Another brick in the wall?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32495299|t=2020. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32398164|t=2020. Drug repurposing against COVID-19: focus on anticancer agents.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32509284|t=2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32395245|t=2020. Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32360293|t=2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32422152|t=2020. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32533263|t=2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32405780|t=2020. Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32383582|t=2020. When the Others Become Us: A Chemist's Perspective of the COVID-19 Outbreak in Italy.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32432466|t=2020. Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32402186|t=2020. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32428392|t=2020. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32478500|t=2020. COVID-19 and Other Pandemics: How Might They Be Prevented?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519842|t=2020. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32469114|t=2020. An update on ACE2 amplification and its therapeutic potential.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32350686|t=2020. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32454090|t=2020. The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534451|t=2020. Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32489694|t=2020. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32489692|t=2020. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32516203|t=2020. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32406904|t=2020. Clinical trials: management of investigational products during the coronavirus (COVID-19) pandemic.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32479920|t=2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32310688|t=2020. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32315803|t=2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519895|t=2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519894|t=2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519892|t=2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32297590|t=2020. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32499129|t=2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32505720|t=2020. Positive Outcome in a COVID-19 patient with Common Variable Immunodeficiency after IVIG.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534022|t=2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534944|t=2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32405693|t=2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32436029|t=2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32489437|t=2020. Clinical trials for coronavirus disease 2019: What is being evaluated and what is not.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32513797|t=2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32440665|t=2020. Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some Countries.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32493626|t=2020. S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32345532|t=2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399097|t=2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399096|t=2020. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399095|t=2020. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399094|t=2020. Statins and the COVID-19 main protease: in silico evidence on direct interaction.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399093|t=2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32514689|t=2020. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32446195|t=2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32399655|t=2020. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32470547|t=2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32440566|t=2020. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32458149|t=2020. Can Zn Be a Critical Element in COVID-19 Treatment?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32532623|t=2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32426388|t=2020. Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32426387|t=2020. Artificial intelligence approach fighting COVID-19 with repurposing drugs.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534226|t=2020. Monoclonal antibody as a potential anti-COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32410772|t=2020. Emerging pharmacotherapies for COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32519753|t=2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32383371|t=2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32508168|t=2020. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32401215|t=2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32410266|t=2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32391920|t=2020. Consider TLR5 for new therapeutic development against COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32422320|t=2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32454981|t=2020. Current regulatory approaches for accessing potential COVID-19 therapies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32468385|t=2020. Musings on the current state of COVID-19 modeling and reporting.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32435882|t=2020. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32406687|t=2020. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32452670|t=2020. Immunity-Boosting Spices and the Novel Coronavirus.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32525650|t=2020. Targeting SARS-CoV-2: Novel Source of Antiviral Compound(s) against COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534130|t=2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32525715|t=2020. Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32396382|t=2020. Myth Busters: Dietary Supplements and COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32523147|t=2020. Anotaciones breves sobre el sindrome de liberacion de citocinas y el bloqueo terapeutico de la interleucina-6 en SARS-CoV-2/COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32523144|t=2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32518135|t=2020. Paediatric treatment trials for COVID-19 are an ethical imperative.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32522067|t=2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32521191|t=2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32515023|t=2020. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32533795|t=2020. Further aspects of doxycycline therapy in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32533990|t=2020. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32529218|t=2020. Statin therapy in COVID-19 infection: much more than a single pathway.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32520031|t=2020. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32380847|t=2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32516380|t=2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32515404|t=2020. Comprehensive overview of COVID-19 clinical trials.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32515383|t=2020. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32395418|t=2020. An Update on Current Therapeutic Drugs Treating COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32391242|t=2020. A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32467020|t=2020. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425691|t=2020. ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32385829|t=2020. COVID-19 and off label use of drugs: an ethical viewpoint.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32449265|t=2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32418299|t=2020. The COVID-19 chemoprophylactic conundrum: Are we limiting available resources?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32406143|t=2020. Could patients taking isotretinoin therapy be immune against SARS-CoV-2?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32390307|t=2020. Practical tips for using masks in the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32358890|t=2020. Cutaneous side-effects of the potential COVID-19 drugs.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32428864|t=2020. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32514859|t=2020. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32451923|t=2020. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32523611|t=2020. A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32499832|t=2020. Pharmacological treatment of COVID-19: lights and shadows.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32520599|t=2020. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32469436|t=2020. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32378805|t=2020. COVID-19 and toxicity from potential treatments: Panacea or poison.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32475694|t=2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32482569|t=2020. Nutricion Clinica en tiempos de COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32495654|t=2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32379302|t=2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32518390|t=2020. Editorial: Nutrition and COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32433599|t=2020. Nutritional management of COVID-19 patients in a rehabilitation unit.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32404899|t=2020. Clinical significance of nutritional risk screening for older adult patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32414641|t=2020. The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32430428|t=2020. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32398309|t=2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32398976|t=2020. siRNA could be a potential therapy for COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32518634|t=2020. Lithium and coronaviral infections. A scoping review.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32518636|t=2020. A snapshot of the ongoing clinical research on COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32395702|t=2020. The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32426374|t=2020. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32425923|t=2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32390971|t=2020. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32468851|t=2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32406749|t=2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32406253|t=2020. Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32523109|t=2020. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32501513|t=2020. How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32433861|t=2020. How to Discover Antiviral Drugs Quickly.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32515974|t=2020. Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32514101|t=2020. First antibody against COVID-19 spike protein enters phase I.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32529963|t=2020. Can lactoferrin boost human immunity against COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32409452|t=2020. Pandemic could add noise to clinical trial data.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32527823|t=2020. Aggregating data from COVID-19 trials.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32527819|t=2020. Can existing live vaccines prevent COVID-19?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32520641|t=2020. Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32520639|t=2020. Response to Kim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32470338|t=2020. MORTALITY FROM COVID-19 INCREASES WITH UNSATURATED FAT, AND MAY BE REDUCED BY EARLY CALCIUM AND ALBUMIN SUPPLEMENTATION.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32446698|t=2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32427166|t=2020. Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | ===007===
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32476308|t=2020. Empirical Treatment and Prevention of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32466136|t=2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32486229|t=2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32481690|t=2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471278|t=2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471272|t=2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32443911|t=2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429099|t=2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32392184|t=2020. Clinical trials for COVID-19 should include sex as a variable.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32293020|t=2020. Palliativ farmakologisk behandling vid svar covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32444382|t=2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442946|t=2020. inverted question markBCG versus COVID-19?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32162896|t=2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32408547|t=2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32486364|t=2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32486488|t=2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32423024|t=2020. The Rationale for Potential Pharmacotherapy of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32434254|t=2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32381590|t=2020. Ethics of controlled human infection to address COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32395792|t=2020. COVID-19: Main therapeutic options.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32507409|t=2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32486283|t=2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397643|t=2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32485102|t=2020. Current Perspective of Antiviral Strategies against COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369098|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398377|t=2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32462848|t=2020. Interleukine-1 et blocage du COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495979|t=2020. Emergence of novel coronavirus and progress toward treatment and vaccine.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32500793|t=2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32433189|t=2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32391659|t=2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32057209|t=2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397700|t=2020. [Analysis of application of herd immunity as a control strategy for COVID-19].|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490731|t=2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32403995|t=2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32499303|t=2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496239|t=2020. Potential pharmacological agents for COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32496237|t=2020. AYUSH for COVID-19: Science or Superstition?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32510105|t=2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32505909|t=2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32492560|t=2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32442323|t=2020. Curcumin as a potential treatment for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32430996|t=2020. Potential effects of curcumin in the treatment of COVID-19 infection.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32492211|t=2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32492205|t=2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32421836|t=2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32427774|t=2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427277|t=2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495940|t=2020. Probiotics and COVID-19: is there any link?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504751|t=2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505910|t=2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32502901|t=2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32505070|t=2020. Nebulized Lidocaine in COVID-19, An Hypothesis.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32369285|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369284|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369283|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369282|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369281|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32325475|t=2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32393915|t=2020. Biggest COVID-19 trial tests repurposed drugs first.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32417850|t=2020. Drug researchers pursue new lines of attack against COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32415300|t=2020. Biotech companies prepare for COVID-19 downturn.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32415251|t=2020. 15 drugs being tested to treat COVID-19 and how they would work.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32422645|t=2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32415276|t=2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32409766|t=2020. Dozens of coronavirus drugs are in development - what happens next?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32405023|t=2020. Coronavirus drugs trials must get bigger and more collaborative.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504019|t=2020. The coronavirus outbreak could make it quicker and easier to trial drugs.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32424192|t=2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32324361|t=2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32398330|t=2020. A Call for Pediatric COVID-19 Clinical Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423342|t=2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393419|t=2020. Recent advances of therapeutic targets and potential drugs of COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32472655|t=2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501634|t=2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32488956|t=2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32439730|t=2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32385052|t=2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32381697|t=2020. The race is on for antibodies that stop the new coronavirus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32381692|t=2020. Combination prevention for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32461212|t=2020. Reducing transmission of SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32385101|t=2020. Rapid repurposing of drugs for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32327575|t=2020. NIH organizes hunt for drugs.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32409433|t=2020. Antivirals for COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32294756|t=2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32512271|t=2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32448098|t=2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32448085|t=2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32431217|t=2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32469418|t=2020. Evaluation of potential therapeutic options for COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32441805|t=2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437001|t=2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32472779|t=2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32508069|t=2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470199|t=2020. Metformin use amid coronavirus disease 2019 pandemic.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458475|t=2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32458425|t=2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32428941|t=2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32449669|t=2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32495917|t=2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32427004|t=2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32452701|t=2020. An up-to-date overview of computational polypharmacology in modern drug discovery.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32447996|t=2020. Treatments in the COVID-19 pandemic: an update on clinical trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475183|t=2020. Does lopinavir measure up in the treatment of COVID-19?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32282262|t=2020. Treatment considerations for coronavirus (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469280|t=2020. COVID-19: Gene Transfer to the Rescue?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423245|t=2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32212981|t=2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501133|t=2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503817|t=2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503816|t=2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32503814|t=2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32468014|t=2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32310670|t=2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32443151|t=2020. Lopinavir pharmacokinetics in COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462858|t=2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469279|t=2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32462988|t=2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32475223|t=2020. Antiviral effects of probiotic metabolites on COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462970|t=2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32462996|t=2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32476574|t=2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32433345|t=2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32473010|t=2020. TPE-nAbs combination therapy for severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32220033|t=2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32511912|t=2020. COVID-19: Drug targets and potential treatments.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469301|t=2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32472703|t=2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427773|t=2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32364561|t=2020. Randomized Clinical Trials and COVID-19: Managing Expectations.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463427|t=2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453363|t=2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32506195|t=2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32463794|t=2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32434272|t=2020. COVID-19Clinical trials: quality matters more than quantity.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505821|t=2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32455629|t=2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32454500|t=2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453693|t=2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453692|t=2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32267762|t=2020. Research towards treating COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441783|t=2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441764|t=2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32424836|t=2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449802|t=2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512007|t=2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32445484|t=2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438446|t=2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32508009|t=2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441462|t=2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511867|t=2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418327|t=2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32420947|t=2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420936|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32425152|t=2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506621|t=2020. Drugs being investigated for children with COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32423954|t=2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32510142|t=2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407491|t=2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32345591|t=2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32303505|t=2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32480418|t=2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32498751|t=2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412788|t=2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503806|t=2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474583|t=2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32459003|t=2020. A role for retinoids in the treatment of COVID-19?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32459832|t=2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32498131|t=2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32350861|t=2020. COVID-19: A Defining Moment for Clinical Pharmacology?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442315|t=2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32212378|t=2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32284037|t=2020. Perspective on the COVID-19 Coronavirus Outbreak.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32174284|t=2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32400323|t=2020. In vitro data of current therapies for SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427000|t=2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | {{tp|p=32416679|t=2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32394841|t=2020. COVID-19: An Update on Clinical Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32282303|t=2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475041|t=2020. Potential role of Anti-IL-17 in COVID-19 treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510814|t=2020. Omalizumab and COVID19 Treatment: Could It Help?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510734|t=2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32419517|t=2020. Emerging therapies for COVID-19 pneumonia.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429703|t=2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32419524|t=2020. Old and re-purposed drugs for the treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32223349|t=2020. How could artificial intelligence aid in the fight against coronavirus?|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32500928|t=2020. COVID-19 breakthroughs: separating fact from fiction.|pdf=|usr=007}}
| + | |
| | | | |
| | | | |
| − | {{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=007}}
| + | A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea. |
| | + | This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world |
| | + | vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents. |
| | + | Paper is (not yet in PubMed) : |
| | | | |
| − | {{tp|p=32401673|t=2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.|pdf=|usr=007}}
| + | *'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]''' |
| | + | credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today. |
| | + | based on e.g. |
| | | | |
| − | {{tp|p=32428965|t=2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.|pdf=|usr=007}} | + | {{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}} |
| − | {{tp|p=32479158|t=2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32464083|t=2020. P-selectin blockade in COVID-19-related ARDS.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=007}}
| + | |
| | | | |
| | + | ======================================================================================= |
| | | | |
| − | {{tp|p=32446312|t=2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.|pdf=|usr=007}}
| + | COVID19 is now a CURABLE disease !!! |
| − | {{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
| + | |
| | | | |
| − | {{tp|p=32340978|t=2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.|pdf=|usr=007}}
| + | ======================================================================================= |
| − | -rest-
| + | |
| − | {{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
| + | |
| − | {{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats |pdf=|usr=}}
| + | |
| − | {{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
| + | |
| − | {{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
| + | |
| − | {{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
| + | |
| − | {{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
| + | |
| − | {{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
| + | |
| − | {{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
| + | |
| − | {{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
| + | |
| − | {{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
| + | |
| − | {{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
| + | |
